Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Do Caregivers Notice Improved Mood and Social Engagement in Dementia Patients with Cannabis Use? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As dementia progresses, emotional withdrawal and social isolation often become as distressing as memory loss. Families frequently describe their loved ones as “present but distant.” Traditional medications for agitation or depression can sometimes worsen apathy or confusion. This has led caregivers to ask whether cannabis-based medicinal products (CBPMs) might help restore a sense of calm or connection. 

According to NICE guidance NG144 and NHS England, cannabis-based medicines are not licensed for dementia, and evidence for emotional or behavioural benefits remains limited. Yet observational data and caregiver feedback from recent studies suggest that some patients may appear more relaxed and socially engaged after supervised use of low-dose cannabinoid oils. 

Can medical cannabis be accessed legally for women’s health?

What Caregivers Are Reporting in Studies 

In a 2022 Frontiers in Aging Neuroscience study, caregivers in long-term care settings reported that residents using oral THC: CBD oil appeared “less irritable” and “more responsive” during social interaction. While the research primarily assessed agitation, many carers noticed improved emotional expression and a calmer atmosphere. 

Similar findings emerged from Israel’s 2024 cohort study, which followed older adults receiving supervised cannabis oil for agitation. Caregivers observed better eye contact, more willingness to engage in activities, and reduced repetitive behaviours. The improvements often coincided with better sleep and reduced anxiety, suggesting indirect effects on mood. 

In Health Canada’s 2023 therapeutic review, caregivers of older adults described “greater calm and sociability” with CBD-rich oils, though the evidence base was classified as low quality and reliant on self-report. 

What Clinicians Emphasise 

The Medicines and Healthcare products Regulatory Agency (MHRA) notes that any apparent emotional benefits must be weighed against side effects such as sedation or confusion. Prescribing is restricted to specialists on the GMC Register under the Human Medicines Regulations 2012. Clinicians stress that while caregiver reports are valuable, they cannot replace rigorous clinical evidence. 

Clinical Bottom Line 

  • Caregivers often describe improved calmness and sociability after cannabis use. 
  • Reported mood benefits are subjective and not proven in large-scale trials. 
  • NICE and NHS England do not approve CBPMs for dementia treatment. 
  • Clinicians recommend specialist oversight to minimise sedation or confusion. 
  • CBD-dominant products may be better tolerated than THC-rich formulations. 

Role Of AlleviMed 

Educational resources such as AlleviMed provide factual information about how medical cannabis is regulated in the UK. They help families understand eligibility standards, legal frameworks, and safety monitoring but do not offer prescriptions or clinical advice. AlleviMed encourages open discussion with qualified clinicians when exploring unlicensed cannabis use in dementia. 

Takeaway 

Many caregivers have noticed calmer mood and greater social engagement in dementia patients following supervised cannabis use, though the evidence remains anecdotal. National guidance from NICE and NHS England continues to recommend caution until stronger data confirm consistent benefits. Families interested in this approach should always seek specialist input to ensure safety and ethical prescribing. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories